Europe Monoclonal Antibodies Market size exceeded USD 49.5 billion in 2021 and is anticipated to exhibit a 12.3% CAGR from 2022 to 2028.

Monoclonal antibodies are a type of protein that can bind to specific cells. These are identical immunoglobulins produced from a single B-cell that identifies an antigen's unique binding site. Due to their specificity to specific epitopes, mAbs are increasingly being used for diagnostic and therapeutic purposes in a variety of diseases. There are currently large number of monoclonal antibodies on the market to treat blood disorders, cardiovascular disease, cancer, autoimmune disease, and infectious diseases among others. 

Get more details on this report - Request Free Sample PDF

Strong emphasis on research and development activities, coupled with increased investment in product development, will assist industry players in capitalising on untapped market growth opportunities. The market players are combining their expertise to introduce novel mAb therapies to treat a various complex disease. For instance, AbbVie entered into a collaboration agreement with I-Mab for the development and commercialization of Lemzoparlimab, a novel anti-CD47 monoclonal antibody developed for the treatment of multiple cancers.

Europe Monoclonal Antibodies Market, By Type

The fully human segment accounted for USD 25 billion revenue in 2021. Specificity to human genomes and integration of advanced genetic technologies leading to highly efficient product launches are the major growth factors.

Furthermore, collaborative efforts by leading pharmaceutical and clinical stage development firms will open new opportunities for segment growth. Sanofi recently has acquired Kymab, a company that is developing fully human monoclonal antibodies to target immune-mediated diseases as well as immuno-oncology therapeutics. Sanofi has gain global rights to Kymab's novel fully human mAb candidates.

Europe Market, By Application

The oncology segment in the Europe monoclonal antibodies market will showcase around 12.4% growth rate during the forecast period. The high prevalence rate of cancer in the European population will increase demand for monoclonal antibodies (mAb) in treatment regimens.

According to the World Health Organization, every year approximately 3.7 million new cancer cases are reported in the region. Thus, growing prevalence of cancer will drive the product demand in near future. Additionally, to cater to increasing disease burden, key companies are adopting developmental activities that will offer unprecedented growth opportunities to the segment in future.

Europe Market, By End-use

Get more details on this report - Request Free Sample PDF

The specialty centers segment dominated more than 24% Europe monoclonal antibodies market share in 2021, due to the rising prevalence of infectious and chronic diseases, as well as the increased establishment of specialty centres. Various countries around the world are investing in the establishment of technologically advanced healthcare settings, such as specialty centres, where advanced diagnosis and treatment can be provided to patients.

Furthermore, the pandemic has highlighted the critical importance of high-quality treatment at specialised facilities. As a result, increased investment in medical infrastructure to provide high-quality care will drive the market growth. Further, increasing awareness regarding advanced therapeutics and presence of skilled professionals will contribute to the market revenue.

Europe Market, By Country

Germany monoclonal antibodies market held over 18% revenue share in 2021, attributed to the business expansion of some of the country's leading industry players, who have high product demand. In addition to disease prevalence, Germany's high treatment spending capacity on advanced therapies will benefit the monoclonal antibody industry. Furthermore, continuous technological advancements, improved accessibility, and rising disposable income will have an impact on the industry size.

Competitive Industry Landscape

Some of the notable players involved in the Europe monoclonal antibodies market include AbbVie Inc., Bristol Myers Squibb, Amgen, F. Hoffmann-La Roche, and Novartis AG among others. These companies are undertaking various strategic initiatives to expand their geographic presence and product reach. For instance, In June 2021, Amgen signed an agreement with Kyowa Kirin Co. Ltd., to expand and commercialize KHK4083, a fully human monoclonal antibody for the medication of atopic dermatitis. Such strategic alliance has helped the company in business expansion.